Sorry about the sporadic posting. Been busy lately.
Since I hired on at MD Anderson Cancer Center in 2002, I have admired Dr. John Mendelsohn immensely for what he did in raising awareness of cancer prevention & treatment, as well as raising the profile of MDACC itself. On occasions when I saw him, he had this transcendent glow about him, and not just because his lab coat was the whitest possible shade of white.
This morning, in my daily email digest from the Chronicle, I was saddened enough by the headline about Dr. John Mendelsohn's recent death from a glioblastoma. That ethereal glow of his did not shield him from cancer, nor did his years of oncological research, nor did all the advances in treatment that MDACC pioneered under his watch.
Millions of past and present patients and employees at MDACC will lionize this man. However, the news also leads me to reflect on the side of Mendelsohn those folks will likely overlook. I'm gratified that the article's author, Todd Ackerman, chose not to ignore that side.
Since I hired on at MD Anderson Cancer Center in 2002, I have admired Dr. John Mendelsohn immensely for what he did in raising awareness of cancer prevention & treatment, as well as raising the profile of MDACC itself. On occasions when I saw him, he had this transcendent glow about him, and not just because his lab coat was the whitest possible shade of white.
This morning, in my daily email digest from the Chronicle, I was saddened enough by the headline about Dr. John Mendelsohn's recent death from a glioblastoma. That ethereal glow of his did not shield him from cancer, nor did his years of oncological research, nor did all the advances in treatment that MDACC pioneered under his watch.
Millions of past and present patients and employees at MDACC will lionize this man. However, the news also leads me to reflect on the side of Mendelsohn those folks will likely overlook. I'm gratified that the article's author, Todd Ackerman, chose not to ignore that side.
RSS Feed